BidaskClub downgraded shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) from a hold rating to a sell rating in a research report sent to investors on Tuesday.

Other equities analysts have also issued research reports about the stock. TheStreet upgraded shares of Jazz Pharmaceuticals PLC from a c+ rating to a b- rating in a research report on Tuesday, March 28th. Cantor Fitzgerald set a $187.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research report on Wednesday, March 1st. Leerink Swann set a $170.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research report on Wednesday, March 1st. Stifel Nicolaus reduced their price target on shares of Jazz Pharmaceuticals PLC from $200.00 to $190.00 and set a buy rating for the company in a research report on Wednesday, March 1st. Finally, Mizuho restated a buy rating and set a $152.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $182.64.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at 158.80 on Tuesday. The company’s 50 day moving average is $152.09 and its 200 day moving average is $135.76. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a market cap of $9.53 billion, a P/E ratio of 24.00 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.42 by $0.01. The company had revenue of $376.10 million for the quarter, compared to the consensus estimate of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. Jazz Pharmaceuticals PLC’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.26 EPS. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $11.00 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-rating-lowered-to-sell-at-bidaskclub/1393692.html.

In other Jazz Pharmaceuticals PLC news, SVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $152.56, for a total transaction of $30,512.00. Following the transaction, the senior vice president now directly owns 22,562 shares of the company’s stock, valued at $3,442,058.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Karen J. Wilson sold 11,458 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $152.24, for a total transaction of $1,744,365.92. Following the transaction, the senior vice president now directly owns 27,158 shares in the company, valued at $4,134,533.92. The disclosure for this sale can be found here. Insiders sold 54,333 shares of company stock worth $8,345,824 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of JAZZ. WFG Advisors LP increased its position in Jazz Pharmaceuticals PLC by 88,302.7% in the fourth quarter. WFG Advisors LP now owns 64,534 shares of the specialty pharmaceutical company’s stock valued at $1,597,000 after buying an additional 64,461 shares during the period. Putnam Investments LLC increased its position in Jazz Pharmaceuticals PLC by 1.4% in the fourth quarter. Putnam Investments LLC now owns 7,668,086 shares of the specialty pharmaceutical company’s stock valued at $836,052,000 after buying an additional 103,648 shares during the period. Clough Capital Partners L P acquired a new position in Jazz Pharmaceuticals PLC during the fourth quarter valued at approximately $5,680,000. AQR Capital Management LLC increased its position in Jazz Pharmaceuticals PLC by 13.0% in the fourth quarter. AQR Capital Management LLC now owns 349,412 shares of the specialty pharmaceutical company’s stock valued at $38,096,000 after buying an additional 40,237 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in Jazz Pharmaceuticals PLC during the fourth quarter valued at approximately $5,670,000. 86.34% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.